# Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

Mohamad Mohty, Florent Malard, Didier Blaise, Noël Milpied, Gérard Socié, Anne Huynh, Oumedaly Reman, Ibrahim Yakoub-Agha, Sabine Furst, Thierry Guillaume, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Mohamad Mohty, Florent Malard, Didier Blaise, Noël Milpied, Gérard Socié, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica, 2016, 102 (1), pp.184 - 191. 10.3324/haematol.2016.150326. hal-01471574

HAL Id: hal-01471574

https://hal.sorbonne-universite.fr/hal-01471574

Submitted on 20 Feb 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

EUROPEAN
HEMATOLOGY
ASSOCIATION

<figure><img src="image_4.png" /></figure>

Ferrata Storti
Foundation

**Haematologica** 2017
Volume 102(1):184-191

**Correspondence:**

mohamad.mohty@inserm.fr

Received: May 31, 2016.

Accepted: August 18, 2016.

Pre-published: August 23, 2016.

doi:10.3324/haematol.2016.150326

Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/184

©2017 Ferrata Storti Foundation

Material published in Haematologica is cov-
ered by copyright. All rights reserved to the
Ferrata Storti Foundation. Copies of articles
are allowed for personal or internal use.
Permission in writing from the publisher is
required for any other use.

<figure><img src="image_5.png" /></figure>

Sequential regimen of clofarabine, cytosine
arabinoside and reduced-intensity conditioned
transplantation for primary refractory acute
myeloid leukemia

Mohamad Mohty,¹,²,³,⁴,⁵ Florent Malard,¹,³,⁴,⁵ Didier Blaise,⁶ Noel Milpied,⁷ Gérard Socié,⁸ Anne Huynh,⁹ Oumédaly Reman,¹⁰ Ibrahim Yakoub-Agha,¹¹ Sabine Furst,⁶ Thierry Guillaume,¹ Resa Tabrizi,⁷ Stéphane Vigouroux,⁷ Pierre Peterlin,¹ Jean El-Cheikh,⁶ Philippe Moreau,¹,² Myriam Labopin⁵ and Patrice Chevallier¹,²

¹Hematology Department, Centre Hospitalier et Universitaire (CHU) de Nantes; ²Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes; ³Centre de Recherche Saint-Antoine, INSERM, UMRS 938; ⁴Université Pierre et Marie Curie, Paris; ⁵Hematology Department, AP-HP, Université Paris 6, Hôpital Saint Antoine; ⁶Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille; ⁷Hematology Department, CHU Haut-Lévêque, Bordeaux; ⁸Service de Greffe de Moelle, AP-HP, Université Paris 7, Hôpital Saint Louis; ⁹Hematology Department, IUCT Oncopole, Toulouse; ¹⁰Institut d'hématologie de Basse Normandie, CHU, Côte de Nacre 14000 Caen and ¹¹CHU de Lille, LIRIC INSERM U995, Université Lille 2, France

ABSTRACT

The prognosis of patients with acute myeloid leukemia in whom primary treatment fails remains very poor. In order to improve such patients' outcome, we conducted a phase 2, prospective, multicenter trial to test the feasibility of a new sequential regimen, combining a short course of intensive chemotherapy and a reduced intensity-conditioning regimen, before allogeneic stem-cell transplantation. Twenty-four patients (median age, 47 years) with acute myeloid leukemia in primary treatment failure were included. Cytogenetic risk was poor in 15 patients (62%) and intermediate in nine (38%). The sequential regimen consisted of clofarabine (30 mg/m²/day) and cytosine arabinoside (1 g/m²/day) for 5 days, followed, after a 3-day rest, by reduced-intensity conditioning and allogeneic stem-cell transplantation combining cyclophosphamide (60 mg/kg), intravenous busulfan (3.2 mg/kg/day) for 2 days and anti-thymocyte globulin (2.5 mg/kg/day) for 2 days. Patients in complete remission at day +120 received prophylactic donor lymphocyte infusion. Eighteen patients (75%) achieved complete remission. With a median follow-up of 24.6 months, the Kaplan-Meier estimate of overall survival was 54% (95% CI: 33-71) at 1 year and 38% (95% CI: 18-46) at 2 years. The Kaplan-Meier estimate of leukemia-free survival was 46% (95% CI: 26-64) at 1 year and 29% (95% CI: 13-48) at 2 years. The cumulative incidence of non-relapse mortality was 8% (95% CI: 1-24) at 1 year and 12% (95% CI: 3-19) at 2 years. Results from this phase 2 prospective multicenter trial endorsed the safety and efficacy of a clofarabine-based sequential reduced-toxicity conditioning regimen, which warrants further investigation. This study was registered at www.clinicaltrials.gov, identifier number: NCT01188174.

Introduction

The prognosis of patients with acute myeloid leukemia (AML) in primary treat-
ment failure remains very poor. Primary treatment failure or primary refractory AML
is defined by failure to achieve a complete hematologic remission (CR) after one or
two courses of induction chemotherapy.¹,² For these patients, the chance of achieving
a CR with another standard or conventional treatment, including the use of interme-
diate- or high-dose cytosine arabinoside (Ara-C) alone or in combination with an

© Ferrata Storti Foundation
anthracycline, fludarabine or gemtuzumab-ozogamicin, is 10-20% at best. The overall survival rate at 1 year is less than 20%, with a median survival of less than 6 months.³,⁵ In light of these poor results with conventional chemotherapy, allogeneic stem cell transplantation (SCT) represents a potential therapeutic tool for the treatment of patients with refractory AML.⁶ However, standard myeloablative conditioning (MAC), combining cyclophosphamide and either total body irradiation or busulfan, is associated with a very high day +100 overall mortality rate, around 40%⁷⁻¹⁰ in refractory AML patients, precluding its use. Reduced-intensity conditioning (RIC) regimens allowed a significant reduction of non-relapse mortality (NRM), expanding the transplant option to those patients ineligible for standard MAC allogeneic SCT. The RIC regimen aims to take advantage of the graft-versus-leukemia (GvL) effect mediated by the donor's immunocompetent cells, rather than the upfront cytoreductive effect of the conditioning chemotherapy.¹¹ However, in refractory AML, RIC may not control the disease sufficiently to allow a GvL effect to occur. In an attempt to overcome this problem, the so-called "sequential" transplant approach was developed, which combines a short, intensive course of salvage chemotherapy to decrease the leukemia cell burden with RIC. The results achieved with the sequential FLAMSA strategy (fludarabine, intermediate dose Ara-C, amsacrine followed by 4 Gy total body irradiation, cyclophosphamide and anti-thymocyte globulin) developed by the Munich group are among the most promising published so far.¹²,¹³ However, the results are still unsatisfactory in terms of relapse incidence and long-term leukemia control, and the high incidence of severe toxicities, related to amsacrine (mainly cardiotoxicity) and total body irradiation hamper the overall safety and success of the procedure.

Strategies for improving the sequential approach are warranted. Such improvement could be made possible through avoidance of amsacrine and the use of clofarabine and intravenous (i.v.) busulfan in replacement of fludarabine and total body irradiation, respectively. Clofarabine is a next-generation purine analog with significant antileukemic activity, particularly in relapsed AML and acute lymphoblastic leukemia.¹⁴⁻¹⁸ We found that a RIC regimen combining clofarabine, busulfan and anti-thymocyte globulin was safe, with a 1-year NRM rate of 6%, and allowed efficient disease control in AML patients in CR.¹⁹ Thus, the use of clofarabine as an alternative to fludarabine in the setting of RIC allogeneic SCT appears to be very attractive. On the other hand, the antileukemic activity of busulfan is widely recognized, and the favorable safety profile associated with the use of i.v. busulfan is well established.²⁰,²²

We, therefore, conducted a multicenter prospective phase 2 study aiming to assess the efficacy of a sequential regimen combining a short course of intensive chemotherapy based on clofarabine, Ara-C and RIC allogeneic SCT with cyclophosphamide, i.v. busulfan and anti-thymocyte globulin, followed by delayed prophylactic donor lymphocyte infusion (pDLI) in patients with AML in primary treatment failure.

## Methods

### Study design and inclusion criteria

This prospective multicentre phase 2 study included 24 patients diagnosed with AML in primary treatment failure who underwent

allogeneic SCT between 2010 and 2013. The trial was approved by each participating center's institutional review board, the Comité de Protection des Personnes de Tour (CPP Ouest-1, ref. 2009-R29) and the national Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). This study was registered with ClinicalTrials.gov, identifier number: NCT01188174. Informed consent from patients and donors was obtained before their inclusion in the study.

Patients aged between 18 and 55 years were eligible for the study if they had a confirmed diagnosis of AML in the status of primary induction failure, i.e. patients alive after induction treatment but who failed to fulfill the criteria for CR or CR with incomplete recovery.¹,²,³ This was defined by either: (i) the persistence of leukemic blasts in the peripheral blood; or by the persistence of ≥5% leukemic blasts in a representative bone marrow aspiration after a second course of induction chemotherapy; or (ii) persisting hypoplasia, defined by a hypocellular bone marrow and incomplete reconstitution of the cell counts in the peripheral blood, i.e. absolute neutrophil count <0.5×10⁹/L or platelet count <50×10⁹/L at day 100 after starting chemotherapy. Induction chemotherapy itself was administered according to the participating institutions' preference. Additional inclusion criteria were the availability of a matched sibling donor or unrelated stem-cell donor (10-HLA match or a single HLA antigen or allele mismatch).

Exclusion criteria were documented chloroma or leukemic infiltration of the central nervous system, M3 AML, Karnofsky performance score below 60%, serum creatinine above 1.0 mg/dL or creatinine clearance less than 60 mL/min, bilirubin above 1.5 mg/dL, aminotransferases or alkaline phosphatase above 2.5 times the upper normal limit, acute or chronic heart failure, and pregnancy.

### Treatment

Patients included in the study proceeded directly to the sequential allogeneic SCT; however, additional cytoreductive chemotherapy, at the treating physician's discretion, was allowed to control leukemic proliferation while preparation for allogeneic SCT was ongoing. The preparative regimen consisted of 30 mg/m²/day clofarabine and 1 g/m²/day Ara-C for 5 consecutive days (days -13 to -9) and, after a 3-day rest, 60 mg/Kg cyclophosphamide for 1 day (day -5), 3.2 mg/Kg/day i.v. busulfan for 2 consecutive days (days -5 and -4), and 2.5 mg/Kg/day anti-thymocyte globulin for 2 consecutive days (days -3 and -2) (Figure 1). All patients received this treatment as in-patients in private rooms, and remained in hospital until hematopoietic recovery. Day 0 was designated as the day of graft infusion. Supportive care and antimicrobial prophylaxis were as reported previously.²⁴ Of note, supportive care and management of cytomegalovirus infection were homogeneous during the period of the study. Blood products were filtered, irradiated and screened for cytomegalovirus. In the first 100 days after their transplant, patients were assessed at least once a week for cytomegalovirus reactivation, in order to initiate pre-emptive ganciclovir therapy if necessary.

For graft-versus-host disease (GvHD) prophylaxis, patients were given either cyclosporine A alone, in the case of an HLA-matched sibling donor, or cyclosporine A and mycophenolate mofetil, in the case of an HLA-matched unrelated donor.²⁵,²⁶ Per protocol, the dose of mycophenolate mofetil was decreased progressively over 4 weeks, starting from day 35, and that of cyclosporine A from day 62, to be stopped at day 90 if no GvHD appeared. Patients received pDLI if they were in CR in the absence of a history of grade II-IV GvHD after >30 days without immunosuppressive therapy, were free of active infections, and had a documented donor cell chimerism of >80% in peripheral blood T
<figure><img src="image_6.png" /><figcaption>**Figure 1.** Sequential conditioning regimen schema. PBSC: peripheral blood stem cells; pDLI: prophylactic donor lymphocyte infusion; IV: intravenous; UD: unrelated donor.</figcaption></figure>

cells. The first pDLI was given at day +120 or 30 days after discontinuation of immunosuppression. The initial dose was 1×10⁷ CD3⁺ cells/kg for patients with a matched sibling donor, and 1×10⁶ CD3⁺ cells/kg for those with an unrelated donor. In the absence of GvHD, the pDLI dose was escalated (5-fold increase/transfusion), up to three times, every 4 to 6 weeks.

All donor/recipient pairs were typed at the allelic level. A single HLA mismatch out of ten (HLA-A, HLA-B, HLA-Cw, HLA-DRB1 and HLA-DQB1) was allowed at the antigen or allele level. For graft source, granulocyte - colony-stimulating factor-mobilized peripheral blood stem cells were the graft source recommended per protocol, but unmanipulated bone marrow was accepted when peripheral blood stem cells were not available.

## Clinical outcomes and graft-versus-host disease assessment

The overall survival rate at 2 years after transplantation was the primary endpoint. Secondary endpoints included engraftment, leukemia-free survival, leukemia response rate (remission status), relapse rate, treatment-related toxicity, NRM, discontinuation of immunossuppressive therapy, pDLI, acute GvHD and chronic GvHD. Time to neutrophil recovery was defined as the first of 3 consecutive days in which the absolute neutrophil count exceeded 0.5×10⁹/L, and engraftment failure as an absolute neutrophil count above 0.5×10⁹/L at day +42 after allogeneic SCT. Leukemia response rate was evaluated at days +30 and +60, and 6, 12 and 24 months after the transplant. GvHD was evaluated according to the Seattle standard criteria.²⁷

## Statistical methods

The hypothesis for the primary endpoint was an improvement in overall survival at 2 years from 15% to 40%. Using a one step A'Hem procedure, 21 patients would be needed for the statistical analysis to be meaningful. In all, inclusion of 24 patients was planned in order to take account of possible drop outs after inclusion, i.e. patients who would not receive a transplant due to infection or other events occurring after identification of the donor etc., but before the start of conditioning. If the number of surviving patients is seven or more, the hypothesis that the 2-year overall survival rate is less than 15% is rejected with a target error rate of 0.05. If the number of surviving patients at 2 years is six or less, the hypothesis that 2-year overall survival is >40% is rejected with a target error rate of 0.20. Overall and leukemia-free survival rates were calculated using the Kaplan-Meier method. Overall survival was defined as the

time from allogeneic SCT to death, regardless of the cause. Leukemia-free survival was defined as survival with no evidence of leukemia after achieving complete remission. The probability of NRM was calculated using the cumulative incidence procedure. We defined NRM as death with no evidence of leukemia relapse or progression. Data were computed using SPSS and EZR version 1.27 (Saitama Medical Center, Jichi Medical University, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 3.1.1).²⁸

## Results

### Patient and donor characteristics

The characteristics of the patients and the donors are summarized in Tables 1 and 2. The median age of recipients was 47 years (range, 20-57). One patient aged >55 years was included in the trial after approval of the protocol steering committee. AML cytogenetic status, classified according to the European Leukemia Net,²³ was intermediate in 9 patients (38%) and adverse in 15 (62%); no patients had AML with favorable cytogenetics. Seven patients (29%) had a secondary AML (5 secondary to myelodysplastic syndrome and 2 to others malignancies treated by chemotherapy or radiotherapy). The Duval score⁷ was 0 in six patients (25%), 1 in five patients (21%), 2 in six patients (25%) and 3 in seven patients (29%). The diagnosis of AML in primary induction failure was confirmed by the persistence after a second course of induction chemotherapy of leukemic blasts in the peripheral blood in two patients (81% and 89.5%) or of ≥5% leukemic blasts in the bone marrow in 21 patients, while only one patient had persistent hypoplasia. Beside the patient with persistent hypoplasia, the median marrow blast percentage at transplantation was 20% (range, 6-82%). Fifteen donors (62%) were HLA-identical siblings and nine (38%) were unrelated donors. The stem cell source was bone marrow in one case (4%) and peripheral blood stem cells in the remaining 23 (96%). In 11 patients (46%) the Karnofsky score was <90%, whereas in 13 (54%) it was ≥90%.

### Engraftment and chimerism

All patients developed pancytopenia after the sequential conditioning regimen. Twenty-two engrafted (92%) and

© Ferrata Storti Foundation
two died in aplasia. The median time to neutrophil recovery was 15 days (range, 13-56), while the median time to platelet recovery (>50×10⁹/L) was 13 days (range, 7-42). Chimerism was evaluated on CD3⁺ T cells on day +28. Full donor chimerism (donor CD3⁺ T cells ≥95%) was found in 14 patients, while eight patients had mixed chimerism.

## Acute and chronic graft-versus-host-disease

Grade II-IV acute GvHD developed in four patients of whom three had grade II disease at days 9, 12, and 83, and one had grade III GvHD at day 62 after transplantation: no patient developed grade IV acute GvHD. Skin, gut and liver were affected in three, three and one patient, respectively. Acute GvHD resolved in all patients upon corticosteroid treatment. Chronic GvHD developed in nine patients, of whom five had limited disease and four had extensive chronic GvHD.

## Infection and toxicity

Septicemia was encountered in nine patients, caused by bacteria in seven and *Candida albicans* in two. Septicemia led to sepsis or septic shock in three patients. Eight patients developed pneumonia, caused by *Aspergillus* spp. in three patients, bacteria in two, viruses in two, and was of unknown etiology in one patient. Besides viral pneumonia, two patients had cytomegalovirus reactivation, two had Epstein-Barr virus reactivation, one had coronavirus infection and one patient had BK virus-associated hemorrhagic cystitis.

Non-hematologic side effects not related to GvHD or infections were classified according to World Health Organization criteria. Fifteen grade III adverse events were reported in 12 patients; no grade IV adverse event occurred in this study (Table 3). Protocol-related grade III-IV hematologic adverse events were reported in five patients including neutropenia (grade III, n=3; grade IV, n=1), lymphopenia (grade III, n=1; grade IV, n=1), anemia (grade III, n=1), bone marrow failure (grade III, n=1) and pancytopenia (grade III, n=1), with some patients having more than one severe hematologic adverse event.

## Disease response and outcome

At day +30, 23 patients were evaluable for response and one patient had died. Eighteen patients were in CR (75%) and five had persistent leukemia (Tables 2 and 4). One patient with persistent disease at day +30 achieved CR at day +60, without any further treatment beside reduction of immunosuppressive therapy, and maintained it until the last follow-up. Disease relapse after achieving CR occurred in ten patients (42%) at a median of 115 days (range, 49 to 624) after allogeneic SCT. The overall median follow-up after transplant was 24.6 months (range, 23.7-28.6) among surviving patients. Of the 24 patients included in this study, 17 died and seven are still alive at last follow-up. The Kaplan-Meier estimates of overall survival and leukemia-free survival at 2 years were 38% (95% CI: 19-56%) and 29% (95% CI: 13-48%) (Figure 1A,B). Thirteen deaths were directly attributed to disease progression or relapse, whereas four cases were related to the transplant, of which two were related to infection and two to chronic GvHD. At 2 years, the cumulative incidences of relapse/progression and NRM were 54.2% (95% CI: 31.8-72.0) and 12% (95% CI: 3-29%), respectively (Figure 2C,D).

<table><caption>Table 1. Patient and donor characteristics.</caption><thead><tr><th>Characteristic (%)</th><th>Study population (n=24)</th></tr></thead><tbody><tr><td>Patient median age, years (range)*</td><td>47 (20-57)</td></tr><tr><td>Patient gender (female/male) (%)</td><td>9/15 (38%/62%)</td></tr><tr><td>Donor gender (female/male) (%)</td><td>10/14 (42%/58%)</td></tr><tr><td>Sex mismatch (female to male) (%)</td><td>8 (33%)</td></tr><tr><td>Median time from diagnosis to transplantation, days (range)</td><td>122 (73-312)</td></tr><tr><td>Median marrow blasts at transplantation, % (range)**</td><td>20% (6-82)</td></tr><tr><td>Diagnosis</td><td></td></tr><tr><td>De novo AML</td><td>17 (71%)</td></tr><tr><td>AML secondary to MDS</td><td>5 (21%)</td></tr><tr><td>AML secondary to other malignancies</td><td>2 (8%)</td></tr><tr><td>Cytogenetics</td><td></td></tr><tr><td>Intermediate</td><td>9 (38%)</td></tr><tr><td>Unfavorable</td><td>15 (62%)</td></tr><tr><td>Karnofsky score</td><td></td></tr><tr><td>≥ 90%</td><td>13 (54%)</td></tr><tr><td>&lt; 90%</td><td>11 (46%)</td></tr><tr><td>CMV serologic seronegative donor-recipient pairs</td><td></td></tr><tr><td>Stem cell source</td><td></td></tr><tr><td>Bone marrow</td><td>1 (4%)</td></tr><tr><td>PBSC</td><td>23 (96%)</td></tr><tr><td>Donor type</td><td></td></tr><tr><td>Matched sibling donor</td><td>15 (63%)</td></tr><tr><td>Unrelated donor</td><td>9 (37%)***</td></tr><tr><td>Cell dose, median (range)****</td><td></td></tr><tr><td>TNC 10/Kg</td><td>9.0 (3.9-27.5)</td></tr><tr><td>CD34⁺ cells 10/Kg</td><td>7.1 (3.6-8.6)</td></tr></tbody></table>

AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CMV: cytomegalovirus; PBSC: peripheral blood stem cells; TNC: total nucleated cells. *One patient aged >55 years was included in the trial after approval of the protocol steering committee. **One patient had persistent BM hypoplasia and marrow blasts were not evaluable; in two patients BM blasts were not evaluated given the high number of circulating blasts (81% and 89.5%). ***Four patients had a donor with a single anti-genic or allelic mismatch. ****Cell doses are indicated for the 23 patients who received PBSC, the patient who received BM, received 1.79×10⁹/Kg TNC and 1.86×10⁹/Kg CD34⁺ cells.

## Donor lymphocyte infusion

Six of 24 patients (25%) received DLI in our study, including three patients who fulfilled the criteria for pDLI, and three additional patients who received DLI before 30 days without immunosuppressive therapy because of mixed chimerism. Although pDLI could be given from day +120, patients received the first dose on days 132, 173 and 173, due to delayed cyclosporine withdrawal. Patients with mixed chimerism received the first DLI dose earlier, on days 93, 92 and 98. Overall, three patients received one transfusion, two received two transfusions and one received three transfusions in escalating doses. In the DLI group, patients received fewer than three transfusions because of relapse or development of GvHD.

Leukemic relapse occurred in one patient after pDLI and in two after DLI for mixed chimerism, and was the cause of death in all three. GvHD was the main complication after DLI: grade II acute GVHD developed in one patient after DLI for mixed chimerism, and chronic GvHD in all three patients who received pDLI and in one after DLI for mixed chimerism. One patient died from extensive chronic GvHD after pDLI. At the last follow-up, two patients
<table><caption>Table 2. Characteristics of the AML and patients' outcome.</caption><thead><tr><th>Patient</th><th>AML</th><th>Karyotype</th><th>Bone marrow blasts at transplant</th><th>Peripheral blood blasts at transplant</th><th>WBC at transplant × 10<sup>9</sup>/L</th><th>Duval score</th><th>CR at days 30</th><th>Relapse after CR</th><th>Death (yes/no)</th><th>Cause of death</th></tr></thead><tbody><tr><td>01001</td><td>De novo</td><td>Complex</td><td>51</td><td>2</td><td>6.9</td><td>3</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>01002</td><td>De novo</td><td>Normal</td><td>40.5</td><td>0</td><td>0.8</td><td>1</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>01003</td><td>De novo</td><td>-7; t(3;3)</td><td>-</td><td>89.5</td><td>6.6</td><td>3</td><td>No</td><td>-</td><td>Yes</td><td>AML</td></tr><tr><td>01004</td><td>Secondary to MDS</td><td>Del(2q)</td><td>7.5</td><td>0</td><td>0.7</td><td>0</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>01005</td><td>De novo</td><td>Complex</td><td>39</td><td>0</td><td>1.3</td><td>1</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>01006</td><td>De novo</td><td>Complex</td><td>-</td><td>81</td><td>43.7</td><td>3</td><td>No</td><td>-</td><td>Yes</td><td>AML</td></tr><tr><td>02001</td><td>Secondary to MDS</td><td>abn 7</td><td>14</td><td>0</td><td>4.6</td><td>0</td><td>-</td><td>-</td><td>Yes</td><td>Infection</td></tr><tr><td>02002</td><td>Secondary to solid tumor</td><td>Complex</td><td>52</td><td>54</td><td>1.6</td><td>3</td><td>No</td><td>-</td><td>Yes</td><td>AML</td></tr><tr><td>02003</td><td>De novo</td><td>Normal</td><td>7</td><td>0</td><td>1.1</td><td>0</td><td>Yes</td><td>No</td><td>Yes</td><td>Infection</td></tr><tr><td>02004</td><td>De novo</td><td>Complex</td><td>24</td><td>0</td><td>.7</td><td>2</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>06001</td><td>De novo</td><td>Normal</td><td>8</td><td>0</td><td>4.2</td><td>0</td><td>No*</td><td>No</td><td>No</td><td>-</td></tr><tr><td>07001</td><td>Secondary to lymphoma</td><td>+4, t(7;14)</td><td>51</td><td>0</td><td>1.3</td><td>1</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>08001</td><td>De novo</td><td>Complex</td><td>20</td><td>5</td><td>1.6</td><td>2</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>08002</td><td>De novo</td><td>Complex</td><td>39</td><td>55</td><td>3.3</td><td>2</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>09001</td><td>Secondary to MDS</td><td>-7</td><td>6</td><td>10</td><td>1.2</td><td>3</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>09002</td><td>De novo</td><td>Complex</td><td>72</td><td>65</td><td>6.6</td><td>3</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>09003</td><td>De novo</td><td>Complex</td><td>1</td><td>0</td><td>1.0</td><td>1</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>09004</td><td>Secondary to MDS</td><td>Complex</td><td>12</td><td>0</td><td>0.7</td><td>3</td><td>Yes</td><td>No</td><td>Yes</td><td>cGvHD</td></tr><tr><td>09005</td><td>De novo</td><td>t(6;9) (p23;q34)</td><td>11</td><td>0</td><td>5.6</td><td>1</td><td>Yes</td><td>Yes</td><td>Yes</td><td>AML</td></tr><tr><td>09006</td><td>De novo</td><td>-7</td><td>82</td><td>0</td><td>0.3</td><td>2</td><td>Yes</td><td>No</td><td>Yes</td><td>cGvHD</td></tr><tr><td>09007</td><td>De novo</td><td>Normal</td><td>8</td><td>0</td><td>1.7</td><td>0</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>10001</td><td>De novo</td><td>Complex</td><td>6</td><td>0</td><td>1.7</td><td>2</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>10002</td><td>De novo</td><td>+8</td><td>60</td><td>2</td><td>1.3</td><td>2</td><td>Yes</td><td>No</td><td>No</td><td>-</td></tr><tr><td>10004</td><td>Secondary to MDS</td><td>-7q</td><td>12</td><td>0</td><td>0</td><td>0</td><td>No</td><td>Yes</td><td>Yes</td><td>AML</td></tr></tbody></table>

AML: acute myeloid leukemia; WBC: white blood count; CR: complete remission; MDS: myelodysplastic syndrome; abn: abnormality; cGvHD: chronic graft-versus-host disease.

were alive in CR. After DLI for mixed chimerism, all three patients successfully converted to full donor chimerism. Among 13 patients alive at day +120, the reasons for not giving pDLI were disease progression or relapse (n=4), a history of grade II-IV acute GvHD (n=4), current chronic GvHD (n=2), infections (n=1), refusal by donor or patient (n=1) or the decision of the physician in charge of the patient (history of grade I acute GvHD; n=1).

Discussion

The sequential transplant approach combining a short course of intensive chemotherapy based on clofarabine and Ara-C and a RIC allogeneic SCT, evaluated in the current phase 2 prospective study, has successfully fulfilled its objective to achieve limited toxicity while retaining substantial antileukemia activity. In a heavily pretreated population, having received two induction chemotherapy courses, with a median age of 47 years (range, 20-57) and a Karnofsky score <90% in 46% of patients, we found a 2-year NRM rate of 12% and no grade IV non-hematologic adverse events. This favorably compared with standard MAC regimens,⁹,¹⁰,²⁹ but also with the sequential FLAMSA strategy. In the long-term update of the FLAMSA study, Schmidt *et al.* reported a 2-year NRM incidence of

22.2%,¹³ consistent with further reports evaluating the FLAMSA strategy.³⁰,³¹ A retrospective study recently reported a 1-year NRM incidence of 24% after allogeneic SCT for AML in primary induction failure, with no significant difference, according to multivariate analysis, in NRM between patients treated with MAC, RIC or FLAMSA regimens.³² Thus, our approach avoiding amsacrine and replacing fludarabine and total body irradiation by clofarabine and i.v. bulsufan, respectively, fulfilled its objective to decrease toxicity with a very low incidence of NRM, comparable to that observed after the reduced toxicity regimen based on fludarabine and i.v. busulfan.³³,³⁴

Decreased toxicity was not achieved at the expense of less antitumor efficacy. Our sequential conditioning regimen approach still exerts an antileukemic effect in patients with AML in primary treatment failure, 75% of whom achieved CR by day 30 after their transplant. This may appear lower than the 88% CR rate achieved by day 30 using the FLAMSA approach;¹² however, the latter study included both patients with refractory and relapsed AML and 21% (16/75) of patients were already in CR before allogeneic SCT in that study. In contrast, in our trial, all patients had primary refractory AML and, therefore, active disease at the time of transplantation. Furthermore, 62% of our patients had unfavorable cytogenetics and 29% had secondary AML. Thus, our sequential approach

<footnote>*Patient 06001 achieved complete remission at day +60.</footnote>
<figure><img src="image_7.png" /><figcaption>**Figure 2.** Outcome after allogeneic SCT. (A) Two-year overall survival; (B) 2-year leukemia-free survival; (C) cumulative incidence of relapse/progression; and (D) cumulative incidence of non-relapse mortality.</figcaption></figure>

significantly enhanced the antileukemic effect compared to RIC allogeneic SCT, after which only 45% of patients with active AML achieved CR.³⁵

The 2-year overall survival rate was 38%, similar to the 42% reported by Schmid *et al.* using the FLAMSA sequential regimen,¹² and superior to the 20-30% reported after standard MAC allogeneic SCT.⁸,¹⁰,²⁹ Similarly, Middeke *et al.* reported a 2-year overall survival rate of 43% in relapsed/refractory AML after clofarabine salvage therapy and allogeneic SCT in patients achieving a response.¹⁶ Despite these encouraging results, relapse remains the principal complication, leading to a 2-year leukemia-free survival rate of 29%. We acknowledge that survival curves do not reach a plateau and relapses may continue to occur. However, persistent CR after 2 years in these very high-risk patients is an important achievement since retreatment is possible after late relapse. Of note, a longer interval from transplantation to relapse is associated with an improved survival.³⁶,⁵⁷

Our study was designed to decrease relapse risk in patients achieving CR, with a planned pDLI infusion. However, among 19 patients alive at day +120, only a minority - six patients - received DLI in our study because of early disease relapse/progression or a history of GvHD. Furthermore, among patients treated with DLI, half died from relapse. The use of DLI to enhance the antileukemic

<table><caption>**Table 3.** Non-hematologic organ toxicity according to WHO criteria.</caption><thead><tr><td></td><td>Grade III</td><td>Grade IV</td></tr></thead><tbody><tr><td>Esophagitis</td><td>2</td><td>0</td></tr><tr><td>Asthenia</td><td>2</td><td>0</td></tr><tr><td>Liver</td><td>5</td><td>0</td></tr><tr><td>Hypokalemia</td><td>1</td><td>0</td></tr><tr><td>Renal</td><td>1</td><td>0</td></tr><tr><td>Central nervous system</td><td>1</td><td>0</td></tr><tr><td>Lung</td><td>1</td><td>0</td></tr><tr><td>Skin</td><td>2</td><td>0</td></tr></tbody></table>

effect and decrease relapse in our study was, therefore, a disappointing strategy. In addition, as previously described,³⁸ we observed a relatively high incidence of GvHD after pDLI. It does, therefore, seem indispensable to develop new strategies to prevent relapse after allogeneic SCT. One way to overcome these difficulties would be to perform earlier pDLI while patients are still under immunosuppressive therapy. Furthermore, Goodyear *et al.* reported that early administration of the hypomethylating agent azacytidine in AML patients was
well tolerated, and was associated with a low incidence of GvHD.³⁹ This strategy appears promising and a prospective trial evaluating preemptive azacytidine and DLI in high-risk AML patients is ongoing (NCT01541280). Targeted therapy with FLT3-specific tyrosine kinase inhibitors may also be relevant in specific cases. Preliminary data and case reports suggest that FLT3 tyrosine kinase inhibitors can be effective in the post-transplant setting, particularly for patients who have FLT3 internal tandem duplication.⁴⁰ We may consider early use of these new therapeutic strategies after allogeneic SCT, alone or in combination with pDLI, in order to enhance the GvL effect in patients with AML in primary induction failure. Our clofarabine-based, sequential reduced-toxicity conditioning approach seems to be the best setting in which to evaluate such therapeutic strategies, in order to minimize the risk of cumulative toxicity.

Since this was a phase 2 study, only a limited number of patients were enrolled, precluding the realization of subgroup analyses to evaluate the impact of disease characteristics (cytogenetic, secondary AML...) on patients' outcome. Of note, despite the inclusion and exclusion criteria, we believe that our population is an unselected, representative population of patients with refractory AML as shown by the inclusion of a majority of patients with unfavorable cytogenetics and of patients with proliferative, refractory AML. However, we acknowledge that identifying a suitable donor in a timely manner may be difficult in these patients with very aggressive disease, limiting access to transplantation. Use of haploidentical donors, readily available for nearly all patients,⁴¹ may be promising in this setting.

Overall, in view of the results of the current prospective multicenter study, this sequential conditioning regimen combining clofarabine and Ara-C-based chemotherapy followed by a cyclophosphamide, i.v. bulsufan and anti-thymocyte globulin-based RIC allogeneic SCT appears to be a valid approach/platform in patients with AML with primary treatment failure. This regimen represents a significant improvement in terms of toxicity, with a low NRM. However, relapse remains the principal complication in these patients. Collectively, these results provide a framework for further refinement of the sequential approach designed to improve disease control without increasing tox-

<table><caption>Table 4. Transplant-related events.</caption><thead><tr><th>Characteristic</th><th>Study population (n=24)</th></tr></thead><tbody><tr><td>Median follow-up, months (range)</td><td>25 (24-29)</td></tr><tr><td>Overall survival</td><td></td></tr><tr><td>At 1 year, % (95% CI)</td><td>54% (33-71)</td></tr><tr><td>At 2 years, % (95% CI)</td><td>38% (18-56)</td></tr><tr><td>Leukemia-free survival</td><td></td></tr><tr><td>At 1 year, % (95% CI)</td><td>46% (26-64)</td></tr><tr><td>At 2 years, % (95% CI)</td><td>29% (13-48)</td></tr><tr><td>Non-relapse mortality</td><td></td></tr><tr><td>At 1 year, (cumulative incidence, 95% CI)</td><td>8% (1-24)</td></tr><tr><td>At 2 years, (cumulative incidence, 95% CI)</td><td>12% (3-19)</td></tr><tr><td>Relapse/progression</td><td></td></tr><tr><td>At 1 year, (cumulative incidence, 95% CI)</td><td>41.7% (21.7-60.6)</td></tr><tr><td>At 2 years, (cumulative incidence, 95% CI)</td><td>54.2% (31.8-72.0)</td></tr><tr><td>Response to treatment at day +30</td><td></td></tr><tr><td>No response</td><td>5</td></tr><tr><td>Complete remission</td><td>18</td></tr><tr><td>Not evaluable</td><td>1</td></tr></tbody></table>

icity. Although this approach should, ideally, be validated in a phase 3 randomized trial, the choice of the control arm – MAC, FLAMSA or other reduced toxicity regimen – may be tricky. Finally, any such approaches should include enhanced strategies to prevent relapse after allogeneic SCT.

### Acknowledgments

The authors would like to thank the nursing staff for providing excellent care for our patients. MM thanks Prof. J.V. Melo for critical reading of the manuscript. The study was supported by the "Association for Training, Education and Research in Hematology, Immunology and Transplantation" (ATERHIT). Sanofi (France) provided clofarabine used as part of this study. However, Sanofi was not involved in the study design, data analyses, or manuscript writing.

### Funding

This trial was supported by a grant from the French Ministry of Health and the Institut National du Cancer (INCa) as part of the "Programme Hospitalier de Recherche Clinique (PHRC)."

### References

1. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.

2. Ravandi F. Primary refractory acute myeloid leukaemia - in search of better definitions and therapies. Br J Haematol. 2011;155(4):413-419.

3. Estey E. Treatment of refractory AML. Leukemia. 1996;10(6):932-936.

4. Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or

refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol. 2010;148 (2):217-225.

5. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126 (3):319-327.

6. Appelbaum FR. Who should be transplant-ed for AML? Leukemia. 2001;15(4):680-682.

7. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-3738.

8. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992;80

(4):1090-1093.

9. Oyekunle AA, Kroger N, Zabelina T, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006;37(1):45-50.

10. Singhal S, Powles R, Henslee-Downey PJ, et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant. 2002;29(4):291-295.

11. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.

12. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplanta-
tion, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.

13. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092-1099.

14. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013; 54(4):688-698.

15. Kline JP, Larson RA. Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother. 2005;6(15):2711-2718.

16. Middeke JM, Herbst R, Parmentier S, et al. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016;30(2):261-267.

17. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007;48(10):1922-1930.

18. Pui CH, Jeha S. Clofarabine. Nat Rev Drug Discov. 2005;Suppl:S12-13.

19. Chevallier P, Labopin M, Socie G, et al. Results from a clofarabine-busulfan containing reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase II prospective CLORIC trial. Haematologica. 2014;99(9):1486-1491.

20. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf. 2008;3(1):60-66.

21. Russell JA, Kangaroo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936-1949.

22. Almog S, Kurnik D, Shimoni A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant. 2011;17(1):117-123.

23. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):458-474.

24. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia. 2008;17(11):2168-2177.

25. Brissot E, Chevallier P, Guillaume T, et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant. 2010;45(4):786-788.

26. Malard F, Szydlo RM, Brissot E, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(1):28-34.

27. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.

28. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48(3):452-458.

29. Fung HC, Stein A, Slovak M, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9(12):766-771.

30. Schmid C, Schleuning M, Hentrich M, et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 2008;41(8):721-727.

31. Schmid C, Schleuning M, Tischer J, et al. Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. Bone Marrow Transplant. 2012;47(1):46-53.

32. Hemmati PG, Terwey TH, Na IK, et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. Eur J Haematol. 2015;95(6):498-506.

33. Mohty M, Malard F, Blaise D, et al. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allo-

geneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer. 2015;121(4):562-569.

34. Mohty M, Malard F, Savani BN. High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? Biol Blood Marrow Transplant. 2015;21(4):620-624.

35. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620-1629.

36. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454-459.

37. Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599-1606.

38. Liga M, Triantafyllou E, Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant. 2013;19(1):75-81.

39. Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361-3369.

40. Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplant in FLT3-ITD-positive AML: the role for FLT3 tyrosine kinase inhibitors post transplant. Biol Blood Marrow Transplant. 2016;22(6):982-990.

41. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10-24.